ResearcherThe Royal Melbourne HospitalNo recent work listed

Jordan Santucci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4283-7215; OpenAlex author ID A5103271924. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective interna… Co-author DOI 10.1016/j.ejca.2022.06.042 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Benjamin N. J. Thomson · 1 shared paper, 2022 · strength 0.13
- Paper Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cance… DOI 10.1016/j.ejca.2022.06.042 ↗
Matthew Burge · 1 shared paper, 2022 · strength 0.13
- Paper Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cance… DOI 10.1016/j.ejca.2022.06.042 ↗
Peter Gibbs · 1 shared paper, 2022 · strength 0.13
- Paper Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cance… DOI 10.1016/j.ejca.2022.06.042 ↗
Mehrdad Nikfarjam · 1 shared paper, 2022 · strength 0.13
- Paper Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cance… DOI 10.1016/j.ejca.2022.06.042 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.